About Kapa Biosystems
Kapa Biosystems is a Healthcare company based in Wilmington (United States) founded in 2006, and was acquired by Roche in August 2015. Reagents for next-generation sequencing, PCR, and qPCR are supplied. Its focus areas include Life Sciences, Genomics, Enabling Technologies and Kits and Reagents. Its competitors include GenScript, RareCyte and Sequenta; 3 of its 3 listed competitors have raised funding.
Company details
Kapa Biosystems was founded in 2006 and operates in the life sciences sector, focusing on reagents for PCR, qPCR, and next-generation sequencing. The company is headquartered in Wilmington, Massachusetts, United States, with research, development, and manufacturing facilities located in Cape Town, South Africa. A portfolio of products is provided to support molecular biology applications in laboratories worldwide.
- Headquarters Wilmington, United States
- Stage Acquired
- SectorsHealthcare
- Website kapabiosystems.com
- Social LinkedIn X Facebook
- Acquired by Roche (Aug 2015)
Investors in Kapa Biosystems
Kapa Biosystems has secured backing from 1 investor, including institutional investors. Prominent investors backing the company include Roche.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Pharmaceuticals and diagnostics kits are developed for various diseases. | 1896 | roche.com | Basel, Switzerland |
Investor details for Kapa Biosystems
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Timeline of Kapa Biosystems
2 dated milestones of Kapa Biosystems across 9 years, from founding to its latest funding, stage changes and deals.
- Founded Kapa Biosystems is founded.
- Exit Acquired by Roche.
Competitors of Kapa Biosystems
Kapa Biosystems has 3 listed competitors in our database, 3 of them funded. They include GenScript, RareCyte and Sequenta.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| genscript.com | 2002 | Piscataway, United States | $15M | 5,260 | Reagents and instruments are provided for life sciences research. | |
| rarecyte.com | 2009 | Seattle, United States | $114.33M | 54 | Developer of technologies for the analysis of rare and single cells in the blood | |
| sequenta.com | 2008 | San Francisco, United States | $43.46M | 58 | Immuno-sequencing products are developed for disease diagnostics and treatment. |
Detailed competitors of Kapa Biosystems
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Kapa Biosystems
Websites that share an audience with Kapa Biosystems (kapabiosystems.com).
Websites whose visitors overlap most with Kapa Biosystems. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| illumina.com | 100% | 672.7K | #61,793 | View details | |
| neb.com | 87% | 749.5K | #69,042 | View details | |
| idtdna.com | 84% | 505.8K | #85,096 | View details | |
| qiagen.com | 78% | 458.2K | #105,023 | View details | |
| fluidigm.com | 74% | 1.1K | #14,860,207 | View details | |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 7 similar websites and full traffic analytics for Kapa Biosystems
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 7 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Top companies in Genomics & Gene Therapy Platforms
3 companies that operate in the same segment as Kapa Biosystems (Genomics & Gene Therapy Platforms) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Digital sequencing technology for cancer detection is developed. | 2012 | Redwood City, California, United States | USD 557.5 M | USD 982.02 M | 4,867 | |
Circulating tumor DNA is screened for early cancer detection. | 2016 | Menlo Park, California, United States | USD 2 B | USD 147.17 M | 1,141 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Kapa Biosystems
Kapa Biosystems was founded in 2006.
Kapa Biosystems is headquartered in Wilmington, United States. It is registered at Wilmington, Delaware, United States.
Kapa Biosystems was founded in 2006 and operates in the life sciences sector, focusing on reagents for PCR, qPCR, and next-generation sequencing. The company is headquartered in Wilmington, Massachusetts, United States, with research, development, and manufacturing facilities located in Cape Town, South Africa. A portfolio of products is provided to support molecular biology applications in laboratories worldwide.
Kapa Biosystems has 1 investor. Key investors include Roche.
Yes. Kapa Biosystems was acquired by Roche in August 2015.